Search 

CathPrint - a MedTech company founded in 2006 is based on a unique and patented technology that enables miniaturized, large scale, cost effective catheter and endoscopic applications.

Our mission is to improve patient management as well as increase patient safety by enabling advanced, reliable diagnostic and therapeutic catheters and endoscopes.

Although we are based in Stockholm, Sweden but we work closely with an international mixture of OEM manufacturers, sensor/electronics suppliers, and engineering consulting firms to offer product solutions to companies who wish to develop and sell their own catheters and miniaturized endoscopes.  Our key customers currently are small and medium sized European companies developing advanced catheters and endoscopes.

We offer CathPrint™- a patented design and manufacturing technology for the realization of advanced, reliable catheters and endoscopes. It is based on standard electronics production concepts; like flexible printed wire-boards and surface mounting of components. 

We have had a number of research projects with large companies. Today we are in the midst of establishing production for our first customer, whilst evaluating our technology for several other potential customers as well.

Hence, CathPrint is looking for an investment of 5 MSEK to further strengthen the organization as well as extend marketing and sales.

Etteplan supports Medtech companies with design and development. ISO 13485 certified our 70 consultant engineers and designers help large and small companies develop products in all MDD Classes I-III from idea to production. Offices are located in Stockholm, Uppsala, Halmstad, Lund, Copenhagen and Helsinki offering the following engineering skills: Usability, Innovation Workshops, Industrial Design, Mechanical Engineering, Hardware/Software Development, Project Management, Regulatory Affairs and Documentation

We want to improve the quality of life for 660.000 epilepsy families. (# is the western world only)

We want to give New Freedom and Peace of Mind to patients, parents, and health care professionals.

IctalCare A/S develops and markets a body-worn wireless epilepsy seizure alarm that help people with epilepsy, caregivers and healthcare professional

IctalCare 365 consist of a;
- Disposable electrode
- Reusable detector "Senses"
- Reusable A-Unit (receiver and transmitter)

Timeline;
- Launch 12.12.12 at 12.12 pm in Denmark
- Launch 12th of April 2013 in UK and Germany
- Launch 12th of April 2014 in USA
- Exit 2016

Finance;
- Expected revenue in 2016 is € 23 Million
- Positive cash flow from 2014 - 2015
- Expected EBITDA is € 9.3 Million in 2016 having a gross Margin of 55 %

Business Model
We have Sustainable Competitive Advantage using the Razor blade Model. The disposable electrodes secures a continuous sale and only IctalCare electrodes fit to the reusable "Senses" detector.

The Business Model is designed around a monthly subscription Model however buy on demand will also be possible

KIPAX is a private investor specialized into Medtech and was founded 2010.

Investments have been made for instance into SenseAbues (breath based drug testing), Contego (Embolic Protection Devices), AEEG (Cardiac surgical devices), Zoomcamp (vehicle for disabled persons), and others.

We prefer to invest into early phase startup companies as a co-investor, but not a lead investor.

KIPAX is working in close cooperation with KIPA, a Swedish based IP firm specialized into medical devices.

KIPAX is scouting for new investemnt projects and is  this year represented by Erik Krahbichler.

Likvor AB

Likvor is a medical device company which has developed a system to be used in neurological investigations assessing cerebrospinal fluid (CSF) dynamics. The LIKVOR CELDA® SYSTEM is on the market today.

Product

Likvor’s core product, the CELDA® Instrument is a device to measure the dynamics of the cerebrospinal fluid (“CSF”) system. With increased understanding of the brain and neurological diseases, mapping CSF dynamics is becoming more and more important. CELDA® Instrument offers automatic and standardized protocols for multiple purposes in the diagnostic process – identifying patients suffering from normal pressure hydrocephalus (“NPH”) with dementia like symptoms, mapping CSF dynamics pre- and post-shunt surgery, shunt control, constant flow or constant pressure measurements, tap tests, bolus infusions etc. It is the first and only CE certified instrument in this field and will enable objective comparisons of research data from different clinics and research groups. With its flexibility and easy handling the CELDA® sets a new standard for investigations of CSF-dynamics. CELDA® Instrument is safer for the patient and yields a faster and more accurate diagnosis.

By using the LIKVOR CELDA® SYSTEM hospitals can make huge savings, in costs as they reduce the number of shunt reoperations, and in human suffering.

Likvor AB is marketing the LIKVOR CELDA® SYSTEM and LIKVOR CELDA® TOOLS. The system includes an instrument, a bed and a disposable tube set. The system is the result of over 40 years of research at Umeå University and Umeå University Hospital assessing cerebrospinal fluid (CSF) dynamics. The company has one patent in the US and two patents pending which includes both method and device.

Potential and the market

Statistics show that 1 in 10 dementia patients suffer from NPH. Studies indicate that approximately 1.4 million patients in Europe, USA and Japan suffer from NPH.

The CELDA® SYSTEM was CE certified in 2009, and currently there are 8 systems in clinical use with paying customers in Sweden, Denmark, Finland and the UK. To reach the European market, distributors will be used, two contracts are signed; for the German- and the UK-market. A potential clinical study in the US is being evaluated.

Next step

Likvor is looking for 20 MSK for the next three years. The capital will be used to speed up the market penetration in Europe and recruit sales personnel. Exit could be possible through an industrial buyout, for example from a shunt company.  

Otivio is a Medtech company with technology which improves blood flow to the limbs of patients. This can be used for treatment of chronic ischemic wounds, in particular for patients with reduced peripheral circulation.

Another application is to exploit the improved blood flow to heat or cool patients by using the the limb as a heat exchanger.

Otivio is a coordinator of an EU funded project and are currently looking for funding to strenghten its organization and fund additional activites.

Serendipity's core business is to create new innovative companies based on leading academic research.

Serendipity does this together with leading researchers, motivated entrepreneurs and by working closely with potential customers to ensure that the products and services developed meet the actual needs and requirements of the market. Our product development projects usually involve paying customers. This makes the value creation process more efficient while the product demand becomes more predictable.  

Serendipity began operations in 2004 and has since established and operated more than ten companies; most of them research and development-intensive companies.